1535963-91-7
1535963-91-7 structure
- Name: Satralizumab
- Chemical Name: Satralizumab
- CAS Number: 1535963-91-7
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
- Create Date: 2022-08-21 17:40:16
- Modify Date: 2024-01-14 12:42:35
-
Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2].
| Name | Satralizumab |
|---|
| Description | Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IL-6 |
| In Vivo | Satralizumab (120 mg, Subcutaneously, once every 2 weeks, for 4 weeks) prevents dTAA formation and progression in rattus norvegicus[1]. Animal Model: Rattus norvegicus (forty, male, 10-week-old, four equal groups)[1] Dosage: 120 mg Administration: Subcutaneously, once every 2 weeks, for 4 weeks Result: Prevented dTAA (descending thoracic aorta aneurysm) formation and progression. |
| References |
| No Any Chemical & Physical Properties |